Elicio Therapeutics Reports Second Quarter 2023 Financial Re

ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCOAMPLIFY-7P first patient dosed with ELI-002 7P Completed reverse merger becoming a publicly traded company on Nasdaq...

Related Keywords

Massachusetts Institute Of Technology , Massachusetts , United States , Boston , American , Heather Divecchia , Christopher Haqq , Gloria Gasaatura , Darrell Irvine , Robert Connelly , Elicio Therapeutics Inc , Nasdaq , Securities Exchange , Lifesci Communications , Nature Communications , American Society Of Clinical Oncology , Koch Institute Of Integrative Cancer Research , Chief Executive Officer , Chief Medical Officer , Multicenter Phase , American Society , Clinical Oncology , Annual Meeting , Epstein Barr Virus , Initiate Phase , Net Loss , Nat Commun , Consolidated Statements , Howard Hughes Investigator , Biomedical Engineering , Koch Institute , Integrative Cancer Research , Massachusetts Institute , Securities Exchange Act , Private Securities Litigation Reform Act ,